Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
| Autor: | Daniel Lyons, Cliodhna Murray, Siobhan Hannigan, Jacklyn Sui, Salma Alamin, Niall Conlon, Mary Keogan, Khairin Khalib, Chris Fitzpatrick, Jonathan O’B Hourihane, Michael Carey, J David M Edgar |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Clinical and Experimental Immunology. 209:182-187 |
| ISSN: | 1365-2249 0009-9104 |
| Popis: | Anaphylaxis is a rare side-effect of COVID-19 vaccines. To (a) provide direct advice and reassurance to certain persons with a history of anaphylaxis/complex allergy, in addition to that available in national guidelines, and (b) to provide a medically supervised vaccination, a specialist regional vaccine allergy clinic was established. The main objective was to determine if risk stratification through history can lead to safe COVID-19 vaccination for maximum population coverage. A focused history was taken to establish contraindications to giving COVID-19 vaccines. People who reported a high-risk allergy history were given a vaccine not containing the excipient thought to have directly caused previous anaphylaxis. All vaccines were monitored for 30 min after administration. A total of 206 people were vaccinated between 6 July 2021 and 31 August 2021; Comirnaty (Pfizer-BioNTech) (n = 34), and Janssen (n = 172). In total, 78% were women. Ninety-two people (45%) reported a high-risk allergy history. There were no cases of anaphylaxis. Three people developed urticaria and one of these also developed transient tachycardia. One vaccinee developed a pseudoseizure. Two of 208 people ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|